Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02598388 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
A Phase 2 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 578
- Enrollment target
NCT02598388 is a Phase 2 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 578 participants.
The verdict
NCT02598388, a Phase 2 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 578 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and in HIV-infected adults.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ad26.ZEBOV
- BIOLOGICAL MVA-BN-Filo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 578 participants |
| Start Date | 2015-12-10 |
| Est. Completion | 2018-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02598388
The ClinicalTrials.gov registry entry for NCT02598388 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 578 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02598388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02598388 about?
NCT02598388 is a clinical study titled "Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo". The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and in HIV-infected adults.
What is the current status of trial NCT02598388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 578 participants. The study started on 2015-12-10. Estimated completion is 2018-12-12.
What interventions are being tested in trial NCT02598388?
The interventions under investigation include: Placebo (BIOLOGICAL), Ad26.ZEBOV (BIOLOGICAL), MVA-BN-Filo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02598388?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.